Boston, June 03, 2025 (GLOBE NEWSWIRE) — According to the latest study from BCC Research, the “Global Epigenetics Markets” is projected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029 at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029.
The report offers quantitative and qualitative insights to help readers develop growth strategies, assess the market landscape and make informed business decisions. It covers various therapeutic classes, such as DNMT inhibitors, HDAC inhibitors, IDH inhibitors and EZH2 inhibitors.
The report is segmented by study methods, clinical indications and drug classes. Additionally, it discusses industry growth drivers, restraints, trends, opportunities, competitive landscape and emerging technologies impacting the epigenetics market.
The factors driving the market’s growth include:
Rising Cancer Rates: The increasing prevalence of cancer creates a demand for new treatments and diagnostic tools, driving epigenetic research to develop targeted therapies.
Technological Advances: Innovations in tools like CRISPR and next-generation sequencing enhance our ability to study and manipulate epigenetic modifications, leading to better disease understanding and treatment.
Increased Research Funding: More investment in biomedical research supports the development of new technologies and therapies, fostering innovation in epigenetics.
Precision Medicine: The trend toward personalized treatments based on genetic profiles boosts the importance of epigenetics in developing effective, individualized therapies.
Interest in Liquid Biopsy: Liquid biopsies offer a noninvasive way to detect and monitor diseases, and technological improvements are increasing their clinical adoption.
Request a sample copy of the global market for epigenetics research tools and reagents, IVDs and therapeutics reports.
Report Synopsis
| Report Metric | Details |
| Base year considered | 2023 |
| Forecast period considered | 2024-2029 |
| Base year market size |